Skip to main content
Top
Published in: Clinical Rheumatology 9/2007

01-09-2007 | Brief Report

Antioxidant status after iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis

Authors: Alexandra Balbir-Gurman, Yolanda Braun-Moscovici, Vladimir Livshitz, Daniel Schapira, Doron Markovits, Alexander Rozin, Tatiana Boikaner, A. Menahem Nahir

Published in: Clinical Rheumatology | Issue 9/2007

Login to get access

Abstract

Oxidative stress is involved in pathogenesis of Raynaud’s phenomenon (RP), a hallmark of systemic sclerosis (SSc). Frequent episodes of ischemia–reperfusion may lead to release of free radicals and enhanced lipid peroxidation reflected by elevated levels of malondialdehyde (MDA). The failure of native antioxidants (Catalase [CAT], Superoxide dismutase [SOD], and Ceruloplasmin [CP]) might be crucial in endothelial cells damage in RP. Iloprost (IL) synthetic prostacyclin analogue is currently used in the treatment of SSc patients with RP. The objectives of this study were to compare the serum levels of MDA and CP, CAT and SOD activity in red blood cells hemolysate in SSc patients compared to healthy controls; and to study the effect of 5-days IL infusions on MDA and CP levels, and CAT and SOD activity in SSc patients with RP. Twelve SSc patients were treated with 50 μg IL for 5 days. Blood samples were taken before and after day 1st and after day 5th of IL infusions. Levels of CAT were measured according to the Aebi’s method; SOD, according to the Misra and Fridovich method; MDA, according to Slater’s method; and CP, according to Ravin’s method. Activities of CAT (p < 0.001) and SOD (p < 0.04) were significantly reduced; levels of CP (p < 0.006) and MDA (p < 0.06) were raised in SSc compared to controls. IL infusions caused reduction in MDA (p < 0.0001) levels and enhanced production of SOD (p < 0.006) and CAT (p < 0.003). The levels of CP did not change (p = 0.48). Oxidant status in SSc patients with RP is impaired. Therapy with IL led to normalization of antioxidant activity. We suggest that CAT may be a sensitive and reliable laboratory marker of oxidative stress severity in RP. We found that IL, in addition to its vasoactive properties, has a potential to activate inner antioxidant system. Activation of inner antioxidant activity may explain long-term effect of IL instead of its very short half-life time.
Literature
1.
go back to reference Rodnan GP, Myerowitz RL, Justh GO (1980) Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud’s phenomenon. Medicine (Baltimore) 59:393–408 Rodnan GP, Myerowitz RL, Justh GO (1980) Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud’s phenomenon. Medicine (Baltimore) 59:393–408
2.
go back to reference Murrell DF (1993) A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 28(1):78–85PubMedCrossRef Murrell DF (1993) A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 28(1):78–85PubMedCrossRef
3.
go back to reference Maxwell SR, Lip GY (1997) Reperfusion injury: a review of pathophysiology, clinical manifestations and therapeutic options. Int J Cardiol 58(2):95–117PubMedCrossRef Maxwell SR, Lip GY (1997) Reperfusion injury: a review of pathophysiology, clinical manifestations and therapeutic options. Int J Cardiol 58(2):95–117PubMedCrossRef
4.
go back to reference Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr et al (1994) Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120(3):199–206PubMed Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr et al (1994) Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120(3):199–206PubMed
5.
go back to reference Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23(5):581–590 Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23(5):581–590
6.
go back to reference LeRoy EC, Black CM, Fleischmajer R, Jablonska S, Krieg T, Medsger Jr TA et al (1988) Scleroderma (systemic sclerosis):classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed LeRoy EC, Black CM, Fleischmajer R, Jablonska S, Krieg T, Medsger Jr TA et al (1988) Scleroderma (systemic sclerosis):classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed
7.
go back to reference Ravin HA (1961) An improved colorimetric enzymatic assay of ceruloplasmin. J Lab Clin Med 58:161–168PubMed Ravin HA (1961) An improved colorimetric enzymatic assay of ceruloplasmin. J Lab Clin Med 58:161–168PubMed
8.
go back to reference Aebi H (1974) Catalase. In: Bergmeyer U (ed) Methods of enzymatic analysis. Academic, NY, pp 673–677 Aebi H (1974) Catalase. In: Bergmeyer U (ed) Methods of enzymatic analysis. Academic, NY, pp 673–677
9.
go back to reference Misra HP, Fridovich I (1972) The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 247(10):3470–3475 Misra HP, Fridovich I (1972) The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 247(10):3470–3475
10.
go back to reference Slater TF, Sawyer BC (1971) The stimulatory effects of carbon tetrachloride and other halogenoalkanes on peroxidative reactions in rat liver fractions in vitro. Biochem J 123(5):805–814PubMed Slater TF, Sawyer BC (1971) The stimulatory effects of carbon tetrachloride and other halogenoalkanes on peroxidative reactions in rat liver fractions in vitro. Biochem J 123(5):805–814PubMed
11.
go back to reference Stein CM, Tanner SB, Awad JA, Roberts LJ 2nd, Morrow JD (1996) Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 39(7):1146–1150PubMedCrossRef Stein CM, Tanner SB, Awad JA, Roberts LJ 2nd, Morrow JD (1996) Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 39(7):1146–1150PubMedCrossRef
12.
go back to reference Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MI (1994) Micronutrient antioxidant status in patients with primary Raynaud’s phenomenon and systemic sclerosis. J Rheumatol 21(8):1477–1483PubMed Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MI (1994) Micronutrient antioxidant status in patients with primary Raynaud’s phenomenon and systemic sclerosis. J Rheumatol 21(8):1477–1483PubMed
13.
go back to reference Sambo P, Jannino L, Candela M, Salvi A, Donini M, Dusi S et al (1999) Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion. J Invest Dermatol 112(1):78–84PubMedCrossRef Sambo P, Jannino L, Candela M, Salvi A, Donini M, Dusi S et al (1999) Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion. J Invest Dermatol 112(1):78–84PubMedCrossRef
14.
go back to reference Solans R, Motta C, Sola R, La Ville AE, Lima J, Simeon P et al (2000) Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis: evidence of free radical-mediated injury. Arthritis Rheum 43(4):894–900PubMedCrossRef Solans R, Motta C, Sola R, La Ville AE, Lima J, Simeon P et al (2000) Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis: evidence of free radical-mediated injury. Arthritis Rheum 43(4):894–900PubMedCrossRef
15.
go back to reference Sambo P, Baroni SS, Luchetti M, Paroncini P, Dusi S, Orlandini G et al (2001) Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 44(11):2653–2664PubMedCrossRef Sambo P, Baroni SS, Luchetti M, Paroncini P, Dusi S, Orlandini G et al (2001) Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 44(11):2653–2664PubMedCrossRef
16.
go back to reference Casciola-Rosen L, Wigley F, Rosen A (1997) Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis. J Exp Med 185(1):71–79PubMedCrossRef Casciola-Rosen L, Wigley F, Rosen A (1997) Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis. J Exp Med 185(1):71–79PubMedCrossRef
17.
go back to reference Rozen A, Casciola-Rozen L, Wigley F (1997) Role of metal-catalyzed oxidation reactions in the early pathogenesis of scleroderma. Curr Opin Rheumatol 9(6):538–543CrossRef Rozen A, Casciola-Rozen L, Wigley F (1997) Role of metal-catalyzed oxidation reactions in the early pathogenesis of scleroderma. Curr Opin Rheumatol 9(6):538–543CrossRef
18.
go back to reference Musellim B, Ikitimur H, Uzun H, Ongen G (2006) The oxidant-antioxidant balance in systemic sclerosis cases with interstitial lung involvement. Rheumatol Int 27(2):163–167PubMedCrossRef Musellim B, Ikitimur H, Uzun H, Ongen G (2006) The oxidant-antioxidant balance in systemic sclerosis cases with interstitial lung involvement. Rheumatol Int 27(2):163–167PubMedCrossRef
19.
go back to reference Tikly M, Channa K, Theodorou P, Gulimian M (2006) Lipid peroxidation and trace elements in systemic sclerosis. Clin Rheumatol 25(3):320–324PubMedCrossRef Tikly M, Channa K, Theodorou P, Gulimian M (2006) Lipid peroxidation and trace elements in systemic sclerosis. Clin Rheumatol 25(3):320–324PubMedCrossRef
20.
go back to reference Herrick AL, Matucci Cerinic M (2001) The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 19(1):4–8PubMed Herrick AL, Matucci Cerinic M (2001) The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 19(1):4–8PubMed
21.
go back to reference Das DK, Maulik KN, Moraru II (1995) Gene expression in acute myocardial stress. Induction by hypoxia, ischemia, reperfusion, hyperthermia and oxidative stress. J Mol Cell Cardiol 27(1):181–193PubMedCrossRef Das DK, Maulik KN, Moraru II (1995) Gene expression in acute myocardial stress. Induction by hypoxia, ischemia, reperfusion, hyperthermia and oxidative stress. J Mol Cell Cardiol 27(1):181–193PubMedCrossRef
22.
go back to reference Tsan MF (1993) Superoxide dismutase and pulmonary oxygen toxicity. Proc Soc Exp Biol Med 203(3):286–290PubMed Tsan MF (1993) Superoxide dismutase and pulmonary oxygen toxicity. Proc Soc Exp Biol Med 203(3):286–290PubMed
23.
go back to reference Pronai L, Arimoni S (1992) Decreased plasma superoxide scavenging activity in immunological disorders-carboxyethylgermanium sesquioxide (Ge-132) as a promoter of prednisolone. Biotherapy 1(4):1–8CrossRef Pronai L, Arimoni S (1992) Decreased plasma superoxide scavenging activity in immunological disorders-carboxyethylgermanium sesquioxide (Ge-132) as a promoter of prednisolone. Biotherapy 1(4):1–8CrossRef
24.
go back to reference Morita A, Minami H, Sakakibara N, Sato K, Tsuji T (1996) Elevated plasma superoxide dismutase activity in patients with systemic sclerosis. J Dermatol Sci 11(3):196–201PubMedCrossRef Morita A, Minami H, Sakakibara N, Sato K, Tsuji T (1996) Elevated plasma superoxide dismutase activity in patients with systemic sclerosis. J Dermatol Sci 11(3):196–201PubMedCrossRef
25.
go back to reference Simonini G, Cerinic MM, Generini S, Zoppi M, Anichini M, Cesaretti C et al (1999) Oxidative stress in systemic sclerosis. Mol Cell Biochem 196(1–2):85–91PubMedCrossRef Simonini G, Cerinic MM, Generini S, Zoppi M, Anichini M, Cesaretti C et al (1999) Oxidative stress in systemic sclerosis. Mol Cell Biochem 196(1–2):85–91PubMedCrossRef
26.
go back to reference Yamamoto T, Takagawa S, Katayama I, Mizushima Y, Nishioka K (1999) Effect of superoxide dismutase on bleomycin induced dermal sclerosis: implications for the treatment of systemic sclerosis. J Invest Dermatol 113(5):843–847PubMedCrossRef Yamamoto T, Takagawa S, Katayama I, Mizushima Y, Nishioka K (1999) Effect of superoxide dismutase on bleomycin induced dermal sclerosis: implications for the treatment of systemic sclerosis. J Invest Dermatol 113(5):843–847PubMedCrossRef
27.
go back to reference Mizushima Y, Hoshi K, Yanagawa A, Takano K (1991) Topical application of superoxide dismutase cream. Drugs Exp Clin Res 17(2):127–131PubMed Mizushima Y, Hoshi K, Yanagawa A, Takano K (1991) Topical application of superoxide dismutase cream. Drugs Exp Clin Res 17(2):127–131PubMed
28.
go back to reference Niwa Y, Somiya K, Michelson AM, Puget K (1985) Effect of liposomal-encapsulated superoxide dismutase on active oxygen-related human disorders. A preliminary study. Free Radic Res Commun 1(2):137–153PubMed Niwa Y, Somiya K, Michelson AM, Puget K (1985) Effect of liposomal-encapsulated superoxide dismutase on active oxygen-related human disorders. A preliminary study. Free Radic Res Commun 1(2):137–153PubMed
29.
go back to reference Jayson MI, Davis P, Whicher JT, Walters G (1975) Serum copper and caeruloplasmin in ankylosing spondylitis, systemic sclerosis, and morphea. Ann Rheum Dis 35(5):443–445PubMed Jayson MI, Davis P, Whicher JT, Walters G (1975) Serum copper and caeruloplasmin in ankylosing spondylitis, systemic sclerosis, and morphea. Ann Rheum Dis 35(5):443–445PubMed
30.
go back to reference Mittag M, Beckheinrich P, Haustein UF (2001) Systemic sclerosis-related Raynaud’s phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels. Acta Derm Venereol 81(4):294–297PubMedCrossRef Mittag M, Beckheinrich P, Haustein UF (2001) Systemic sclerosis-related Raynaud’s phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels. Acta Derm Venereol 81(4):294–297PubMedCrossRef
31.
go back to reference Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T et al (2001) Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 108(2):241–250PubMedCrossRef Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T et al (2001) Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 108(2):241–250PubMedCrossRef
32.
go back to reference Mazzone A, Cusa C, Bucci L, Vezzoli M, Ghio S, Buggia I et al (1999) The effects of iloprost infusion on microcirculation is independent of nitric oxide metabolites and endothelin-1 in chronic peripheral ischaemia. Eur J Clin Invest 29(1):1–5PubMedCrossRef Mazzone A, Cusa C, Bucci L, Vezzoli M, Ghio S, Buggia I et al (1999) The effects of iloprost infusion on microcirculation is independent of nitric oxide metabolites and endothelin-1 in chronic peripheral ischaemia. Eur J Clin Invest 29(1):1–5PubMedCrossRef
Metadata
Title
Antioxidant status after iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis
Authors
Alexandra Balbir-Gurman
Yolanda Braun-Moscovici
Vladimir Livshitz
Daniel Schapira
Doron Markovits
Alexander Rozin
Tatiana Boikaner
A. Menahem Nahir
Publication date
01-09-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 9/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-007-0613-2

Other articles of this Issue 9/2007

Clinical Rheumatology 9/2007 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.